ISAR-DAPT (A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial)

Inclusion Criteria: 1. Patients aged 19 or older 2. Patients who have submitted a written consent to participate in the clinical trial 3. De novo lesion 4. Patients scheduled for elective intervention to treat ischemic cardiovascular disease Exclusion Criteria: 1. Patients with any contraindications or hypersensitivity related to antiplatelet therapy 2. Patients with Acute Myocardial Infarction (ST elevation myocardial infarction, Non ST elevation myocardial infarction) 3. Patients who are anticipated to receive treatment or surgery that may require desisting the administration of antiplatelet therapy for 2 weeks or longer during the period of the clinical trial 4. Chronic total occlusion (CTO) lesions, in-stent restenosis (ISR) 5. Patients experiencing cardiogenic shock 6. Women who are breastfeeding, pregnant, or desiring pregnancy 7. Patients with findings of hemorrhage 8. Patients with a life expectancy of less than 1 year 9. Patients who have received a drug-eluting stent (DES) procedure within the past 6 months 10. Any other patients judged by the investigator to be unsuitable for the trial